[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Phathom Pharmaceuticals Inc 100 CAMPUS DRIVE SUITE 102 FLORHAM PARK NJ 07932 USA

www.phathompharma.com Employees: 371 P: 877-742-8466

Sector:

Medical

Description:

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo Grove, United States.

Key Statistics

Overview:

Market Capitalization, $K 903,635
Enterprise Value, $K 982,755
Shares Outstanding, K 79,756
Float, K 72,315
% Float 90.67%
Short Interest, K 9,736
Short Float 12.21%
Days to Cover 5.88
Short Volume Ratio 0.57
% of Insider Shareholders 9.33%
% of Institutional Shareholders 99.01%

Financials:

Annual Sales, $ 175,110 K
Annual Net Income, $ -221,250 K
Last Quarter Sales, $ 58,300 K
Last Quarter Net Income, $ -30,370 K
EBIT, $ -96,600 K
EBITDA, $ -92,950 K

Growth:

1-Year Return 167.85%
3-Year Return -3.66%
5-Year Return -67.95%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 36.86%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.18 on 04/30/26
Next Earnings Date 08/06/26
Earnings Per Share ttm -1.59
EPS Growth vs. Prev Qtr -56.25%
EPS Growth vs. Prev Year 78.26%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

PHAT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -44.29%
Profit Margin % -126.35%
Debt/Equity -0.49
Price/Sales 5.27
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -4.22
Interest Coverage -2.25
60-Month Beta 0.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.